Triochem Posts ₹9.48 Lakh Q1FY27 Profit on Other Income
Triochem Products Ltd reported a Q1FY27 net profit of ₹9.48 lakh, reversing a prior-year loss, despite zero operational revenue. The profit stems from other income of ₹16.56 lakh against reduced expenses. The Board cited post-pandemic challenges in relationship-driven sales but highlighted liquidity comfort following the monetization of non-core assets in the previous year.

*this image is generated using AI for illustrative purposes only.
Triochem Products Limited reported a net profit of ₹9.48 lakh for the quarter ended June 30, 2026, marking a turnaround from the net loss of ₹3.06 lakh recorded in the corresponding period of FY25. The company’s total income for the quarter was ₹16.56 lakh, derived entirely from other income, as revenue from operations remained at zero.
Financial Performance
The unaudited standalone financial results, approved by the Board of Directors on August 14, 2026, reveal a significant divergence between operational activity and bottom-line performance. While the company generated no revenue from its core chemical and pharmaceuticals segment, it managed to reduce expenses to ₹4.17 lakh, down from ₹37.34 lakh in Q1FY25. This reduction was primarily driven by lower employee benefit expenses (₹0.75 lakh vs ₹13.52 lakh) and other expenditure (₹3.42 lakh vs ₹22.18 lakh).
| Metric: | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Revenue from Operations: | ₹0 lakh | ₹0 lakh | — |
| Other Income: | ₹16.56 lakh | ₹22.10 lakh | -25.1% |
| Total Income: | ₹16.56 lakh | ₹22.10 lakh | -25.1% |
| Total Expenses: | ₹4.17 lakh | ₹37.34 lakh | -88.8% |
| Profit Before Tax: | ₹12.39 lakh | (₹15.24 lakh) | Turnaround |
| Net Profit: | ₹9.48 lakh | (₹3.06 lakh) | Turnaround |
The profit before tax stood at ₹12.39 lakh, with a total tax expense of ₹2.91 lakh comprising current tax of ₹2.63 lakh and deferred tax of ₹0.28 lakh. Earnings per share (EPS) were ₹3.87, compared to a loss of ₹1.25 per share in the previous year’s quarter.
Business Outlook and Asset Monetization
During the board meeting, directors discussed the ongoing impact of the post-COVID-19 pandemic on the business model. The company noted that sectors requiring personal presentation and relationship building have faced a "tremendous hit" with no immediate possibility of revival. Regular customer business is shrinking, with no significant improvement expected in the near term.
To address liquidity and strategic needs, Triochem previously approved the sale of certain immovable properties, plant, machinery, and investment properties in Maharashtra. Shareholder approval via postal ballot was obtained in December 2025. The assets, with a written-down value of ₹56.92 lakh, were sold for a fair market value of approximately ₹1,173.20 lakh (₹672.05 lakh for property, plant & machinery and ₹501.15 lakh for investment properties). This resulted in an exceptional gain of ₹1,116.65 lakh, which was recognized in the previous financial year’s results. The proceeds were received in cash and are proposed to be utilized for funding new business ventures and strategic initiatives.
What the Numbers Show
The current quarter’s profitability is entirely non-operational. With zero revenue from operations, the ₹9.48 lakh net profit is driven by other income exceeding minimal operational costs. This highlights the company’s transition phase, where core business activities have effectively paused while management focuses on asset monetization and potential new ventures. The sharp decline in expenses suggests a lean operational structure maintained during this period of low activity.
Regulatory Compliance
The financial results were reviewed by the Audit Committee and approved by the Board in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kanu Doshi Associates LLP, the statutory auditors, issued an unqualified conclusion on the unaudited quarterly financial results. The company confirmed compliance with applicable securities laws and noted that there were no deviations or variations in public issues during the quarter.
Historical Stock Returns for Triochem Products
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
What specific new business ventures or strategic initiatives does Triochem plan to launch using the ₹1,173.20 lakh proceeds from its recent asset sales?
Given the management's assessment that core sectors requiring personal presentation face no immediate revival, what is the timeline for Triochem to exit or restructure its traditional chemical and pharmaceuticals operations?
How will the company's investment strategy evolve now that it has transitioned from a loss-making operational entity to a cash-rich holding structure with minimal ongoing expenses?


































